Business Wire

Inotrem Announces €39 Million Series B Financing to Develop First-In-Class Immunology Therapeutics

Share

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced today a €39 million Series B financing led by Morningside Ventures, joined by Invus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.

The financing will support the clinical development of Inotrem’s lead drug candidate, nangibotide (an anti-TREM-1 peptide) in a global multicentric Phase IIb trial in septic shock patients (ASTONISH trial) to deliver a meaningful proof of clinical efficacy, as well as its companion diagnostic tool using soluble TREM-1 as a mechanism-based biomarker to select patients that are more likely to respond favorably to treatment. This series B financing will also allow Inotrem to expand its TREM-1 franchise to address chronic inflammatory diseases.

“We are thrilled to have attracted world-class investors from the USA to advance what we believe is a new paradigm in immunotherapy” said Jean-Jacques Garaud, CEO of Inotrem, “This financing validates the potential of our technology platform centered on the TREM-1 pathway and of our lead drug candidate for septic shock, nangibotide, which will be entering a large Phase IIb clinical trial later this year”.

Based on a novel approach of immunomodulation which targets the TREM-1 pathway, Inotrem has developed a proprietary technology platform and leverages its extensive knowledge of the TREM-1 pathway biology to develop programs in several indications with inflammatory syndromes for which there is a major and today unsatisfied therapeutic need. Its lead compound, nangibotide, targets septic shock which is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific mechanism-based therapy approved for this indication. Inotrem’s solution has the potential to become the first mechanism-based treatment for septic shock.

“We have been strongly impressed by Inotrem’s achievements until now and are convinced its approach of immunomodulation which targets the TREM-1 pathway could represent a step change in immunotherapy and bring solutions to patients that today lack effective therapies”, indicated Jason Dinges of Morningside.

In connection with the financing, Dr. Jason Dinges of Morningside will join the Inotrem’s Board of Directors.

Bryan Garnier & Co, the European Growth Investment Bank, supported Inotrem with its fundraising.

About Inotrem
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com

About Nangibotide
Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA.

ASTONISH Study
The Efficacy, Safety and Tolerability of nangibotide in Patients with Septic Shock (ASTONISH) phase IIb trial is a Randomized, Double-blind, Placebo Controlled Dose Selection Study that will be performed Europe and the US. Four hundred and fifty patients are planned to be included in this study in 48 clinical sites. The study will compare the effect of nangibotide at two different doses versus standard of care. The IND has been cleared by the FDA in August 2019.

Contact information

Media contact for Inotrem
Anne REIN
S&I
anne.rein@strategiesimage.com
+33 6 03 35 92 05

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running21.1.2020 05:00:00 CETPress release

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) is proud to be named in the Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the fifth consecutive year. Corporate Knights assesses more than 7,300 companies against 21 key performance indicators. It uses these indicators to determine the top 1% most sustainable companies in the world, which are announced annually at the World Economic Forum in Davos, Switzerland. “Building sustainable value is a fundamental part of the way we do business at Takeda, and we are proud to be recognized as a global leader in sustainability,” said Christophe Weber, President and CEO. “This recognition by Corporate Knights is a testament to the strong foundation Takeda has laid and the progress we have already achieved. We remain steadfast in our commitment to realizing Better Health and a Brighter Future for all.” Corporate Knights highlighted Takeda’s performance in the following areas: Significan

Alibaba Cloud Named First Public Cloud Vendor in the World to Obtain Trusted Partner Network (TPN) Certification21.1.2020 02:00:00 CETPress release

Alibaba Cloud, the data intelligence backbone of Alibaba Group, has today announced that it is the first public cloud vendor in the world to obtain the prestigious Trusted Partner Network (TPN) certification, an achievement that validates the entertainment industry’s confidence in its robust security and trustworthiness as a cloud service provider. With viewing consumption habits changing rapidly, broadcast platforms constantly evolving and new production techniques emerging globally, Alibaba Cloud is successfully helping the entertainment industry to revolutionise how it works in order to respond to and embrace these changing dynamics by offering a highly secure, dependable, flexible and scalable cloud-based platform. The TPN is a joint venture between two major entertainment industry associations; the Motion Picture Association of America (MPAA) and the Content Delivery & Security Association (CDSA). The TPN's goal is to help companies to ensure content security, prevent leaks, breac

Logitech Delivers Record Sales and Profitability in Holiday Quarter21.1.2020 02:00:00 CETPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the third quarter of Fiscal Year 2020. Q3 sales were $903 million, up 4 percent in US dollars and 5 percent in constant currency, compared to Q3 of the prior year. Q3 GAAP operating income grew 4 percent to $129 million, compared to $123 million in the same quarter a year ago. Q3 GAAP earnings per share (EPS) grew 3 percent to $0.69, compared to $0.67 in the same quarter a year ago. Q3 non-GAAP operating income grew 6 percent to $152 million, compared to $143 million in the same quarter a year ago. Q3 non-GAAP EPS grew 6 percent to $0.84, compared to $0.79 in the same quarter a year ago. Cash flow from operations was $181 million, compared to $176 million in the same period a year ago. “We delivered our biggest quarter in sales and profit in company history, topping $900 million in quarterly sales for the first time ever,” said Bracken Darrell, Logitech president and chief executive officer. “Our th

HD-PLC Innovates IoT World21.1.2020 01:00:00 CETPress release

In Japan, the High-definition Power Line Communication (HD-PLC) technology has been mostly used in PLC adapters and communication equipment so far. One major reason was the interpretation of the “Ministerial Order to Provide Technical Standards for Electrical Appliances and Materials” which applied to the integration of HD-PLC into home electric appliances and housing equipment. Recently, the efforts of the involved parties have been rewarded by the Notice issued on December 25, 2019 by the Ministry of Economy, Trade and Industry (METI) that partially revised the interpretation of the Ministerial Order. HD-PLC can now be integrated in home appliances and housing equipment. The main advantages of HD-PLC over wireless technologies include an easy setup of communication networks, a high level of security, and low power consumption. Additionally, HD-PLC can be used on power lines, coaxial cables, telephone lines, and other existing lines which not only enables the deployment of networks in

Morris Group of Companies Announces Solicitation for Offers21.1.2020 00:13:00 CETPress release

TAKE NOTICE THAT the Court of Queen’s Bench for Saskatchewan (the “Court”) granted an Order to 101098672 Saskatchewan Ltd., Morris Industries Ltd., Morris Sales and Service Ltd., Contour Realty Inc., and Morris Industries (USA) Inc. (collectively “Morris Group” or the “Companies”) extending their stay of proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) to March 27, 2020 (the “Stay Extension”), enabling the Companies to continue with their efforts to restructure their business and financial affairs, including obtaining Court approval to conduct a Sale and Investment Solicitation Process (the “SISP”). Pursuant to the SISP, Alvarez & Marsal Canada Inc., acting in its capacity as the court appointed Monitor of the Morris Group and not in its personal or corporate capacity (the “Monitor”) is soliciting proposals from prospective strategic and financial parties to acquire the business of, or to invest in the Morris Group. The Morris Group primarily carries on business

European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible20.1.2020 18:43:00 CETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for Darzalex® (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). This approval is based on results from Part one of the Phase 3 CASSIOPEIA (MMY3006) study, published in The Lancet 5 in June 2019 and presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting. “The effectiveness of first-line treatment is critical to maximise time until relapse. So, we asked ourselves, can we improve the standard of care that is bortezomib, thalidomide and dexamethasone (VTd) to provide patients with valuable extra time?” said Philippe Moreau, M.D., principal investigator and Head of the Haematology Department at the University Hospital of Nantes, France. “The CASSIOPEIA study answered that